AstraZeneca and its global biologics research and development arm, MedImmune, have chosen Cambridge as the base for a pioneering new genomics research centre.
AstraZeneca and its global biologics research and development arm, MedImmune, have chosen Cambridge as the base for a pioneering new genomics research centre.